(Z)-7-{(1R,2S,3R,5R)-5-chloro-3-hydroxy-2-[4-((R)-1-hydroxy-hexyl)-phenyl]-cyclopentyl}-hept-5-enoic acid | 890846-36-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (Z)-7-{(1R,2S,3R,5R)-5-chloro-3-hydroxy-2-[4-((R)-1-hydroxy-hexyl)-phenyl]-cyclopentyl}-hept-5-enoic acid
• 英文别名: (Z)-7-[(1R,2S,3R,5R)-5-chloro-3-hydroxy-2-[4-[(1R)-1-hydroxyhexyl]phenyl]cyclopentyl]hept-5-enoic acid
• CAS: 890846-36-3
• 化学式: C₂₄H₃₅ClO₄
• 分子量: 422.993
• InChiKey: ZOXKIFGUQLOEFG-YFUYLENFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  29
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  77.8
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  (Z)-7-{(1 R,2S,3R,5 R)-5-Chloro-3-hydroxy-2-[4-(1-hydroxy-hexyl)-phenyl]-cyclopentyl}-hept-5-enoic acid 生成 (Z)-7-{(1R,2S,3R,5R)-5-chloro-3-hydroxy-2-[4-((R)-1-hydroxy-hexyl)-phenyl]-cyclopentyl}-hept-5-enoic acid 、 (Z)-7-{(1R,2S,3R,5R)-5-chloro-3-hydroxy-2-[4-((S)-1-hydroxy-hexyl)-phenyl]-cyclopentyl}-hept-5-enoic acid
  参考文献：
  名称：

  Therapeutic Substituted Cyclopentanes

  摘要：

  这里披露了治疗化合物。

  公开号：

  US20070129552A1

文献信息

• THERAPEUTIC SUBSTITUTED CYCLOPENTANES
  申请人：Donde Yariv

  公开号：US20080312321A1

  公开（公告）日：2008-12-18

  Therapeutic compounds are disclosed herein.

  本文披露了治疗化合物。
• COMBINATION THERAPY FOR GLAUCOMA
  申请人：Allergan, Inc.

  公开号：EP2288385A2

  公开（公告）日：2011-03-02
• Combination Therapy For Glaucoma
  申请人：Whitcup Scott M.

  公开号：US20110152328A1

  公开（公告）日：2011-06-23

  Disclosed herein is method of treating glaucoma or ocular hypertension comprising administering a prostaglandin agonist and a second therapeutically active agent to a mammal in need thereof, wherein said second therapeutically active agent is selected from: β-Blockers, Adrenergic Agonists, non-selective adrenergic agonists, α2-selective adrenergic agonists, Carbonic Anhydrase Inhibitors, Cholinergic Agonists, direct acting cholinergic agonists, chlolinesterase inhibitors, Glutamate Antagonists, Ca 2+ channel blockers, Prostamides, Prostaglandins, Cannabinoids, and combinations thereof. Compositions and medicaments containing a combination of these two active agents are also disclosed.
• Combination therapy for glaucoma
  申请人：ALLERGAN, INC.

  公开号：US20140235681A1

  公开（公告）日：2014-08-21

  Disclosed herein is method of treating glaucoma or ocular hypertension comprising administering a prostaglandin agonist and a second therapeutically active agent to a mammal in need thereof, wherein said second therapeutically active agent is selected from: β-Blockers, Adrenergic Agonists, non-selective adrenergic agonists, α 2 -selective adrenergic agonists, Carbonic Anhydrase Inhibitors, Cholinergic Agonists, direct acting cholinergic agonists, chlolinesterase inhibitors, Glutamate Antagonists, Ca 2+ channel blockers, Prostamides, Prostaglandins, Cannabinoids, and combinations thereof. Compositions and medicaments containing a combination of these two active agents are also disclosed.
• US7427685B2
  申请人：——

  公开号：US7427685B2

  公开（公告）日：2008-09-23